Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Identifieur interne : 000460 ( Ncbi/Merge ); précédent : 000459; suivant : 000461Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Auteurs : A. Albanese [Italie] ; U. Bonuccelli ; C. Brefel ; K R Chaudhuri ; C. Colosimo ; T. Eichhorn ; E. Melamed ; P. Pollak ; T. Van Laar ; M. ZappiaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- Apomorphine (administration & dosage), Apomorphine (diagnostic use), Apomorphine (pharmacology), Corpus Striatum (drug effects), Decision Making, Domperidone (administration & dosage), Domperidone (diagnostic use), Domperidone (pharmacology), Dopamine Agonists (administration & dosage), Dopamine Agonists (diagnostic use), Dopamine Agonists (pharmacology), Dopamine Antagonists (administration & dosage), Dopamine Antagonists (diagnostic use), Dopamine Antagonists (pharmacology), Drug Administration Schedule, Guidelines as Topic, Humans, Levodopa (administration & dosage), Levodopa (diagnostic use), Levodopa (pharmacology), Parkinson Disease (diagnosis), Substantia Nigra (drug effects), Time Factors.
- MESH :
- chemical , administration & dosage : Apomorphine, Domperidone, Dopamine Agonists, Dopamine Antagonists, Levodopa.
- chemical , diagnostic use : Apomorphine, Domperidone, Dopamine Agonists, Dopamine Antagonists, Levodopa.
- chemical , pharmacology : Apomorphine, Domperidone, Dopamine Agonists, Dopamine Antagonists, Levodopa.
- diagnosis : Parkinson Disease.
- drug effects : Corpus Striatum, Substantia Nigra.
- Decision Making, Drug Administration Schedule, Guidelines as Topic, Humans, Time Factors.
Abstract
Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.
PubMed: 11295770
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003D91
- to stream PubMed, to step Curation: 003D91
- to stream PubMed, to step Checkpoint: 003D80
Links to Exploration step
pubmed:11295770Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.</title><author><name sortKey="Albanese, A" sort="Albanese, A" uniqKey="Albanese A" first="A" last="Albanese">A. Albanese</name><affiliation wicri:level="1"><nlm:affiliation>Istituto di Neurologia, Università Cattolica, Milano, Italy. alberto.albanese@rm.unicatt.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto di Neurologia, Università Cattolica, Milano</wicri:regionArea><wicri:noRegion>Milano</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name></author><author><name sortKey="Chaudhuri, K R" sort="Chaudhuri, K R" uniqKey="Chaudhuri K" first="K R" last="Chaudhuri">K R Chaudhuri</name></author><author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name></author><author><name sortKey="Eichhorn, T" sort="Eichhorn, T" uniqKey="Eichhorn T" first="T" last="Eichhorn">T. Eichhorn</name></author><author><name sortKey="Melamed, E" sort="Melamed, E" uniqKey="Melamed E" first="E" last="Melamed">E. Melamed</name></author><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name></author><author><name sortKey="Van Laar, T" sort="Van Laar, T" uniqKey="Van Laar T" first="T" last="Van Laar">T. Van Laar</name></author><author><name sortKey="Zappia, M" sort="Zappia, M" uniqKey="Zappia M" first="M" last="Zappia">M. Zappia</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11295770</idno><idno type="pmid">11295770</idno><idno type="wicri:Area/PubMed/Corpus">003D91</idno><idno type="wicri:Area/PubMed/Curation">003D91</idno><idno type="wicri:Area/PubMed/Checkpoint">003D80</idno><idno type="wicri:Area/Ncbi/Merge">000460</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.</title><author><name sortKey="Albanese, A" sort="Albanese, A" uniqKey="Albanese A" first="A" last="Albanese">A. Albanese</name><affiliation wicri:level="1"><nlm:affiliation>Istituto di Neurologia, Università Cattolica, Milano, Italy. alberto.albanese@rm.unicatt.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto di Neurologia, Università Cattolica, Milano</wicri:regionArea><wicri:noRegion>Milano</wicri:noRegion></affiliation></author><author><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name></author><author><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name></author><author><name sortKey="Chaudhuri, K R" sort="Chaudhuri, K R" uniqKey="Chaudhuri K" first="K R" last="Chaudhuri">K R Chaudhuri</name></author><author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name></author><author><name sortKey="Eichhorn, T" sort="Eichhorn, T" uniqKey="Eichhorn T" first="T" last="Eichhorn">T. Eichhorn</name></author><author><name sortKey="Melamed, E" sort="Melamed, E" uniqKey="Melamed E" first="E" last="Melamed">E. Melamed</name></author><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name></author><author><name sortKey="Van Laar, T" sort="Van Laar, T" uniqKey="Van Laar T" first="T" last="Van Laar">T. Van Laar</name></author><author><name sortKey="Zappia, M" sort="Zappia, M" uniqKey="Zappia M" first="M" last="Zappia">M. Zappia</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apomorphine (administration & dosage)</term><term>Apomorphine (diagnostic use)</term><term>Apomorphine (pharmacology)</term><term>Corpus Striatum (drug effects)</term><term>Decision Making</term><term>Domperidone (administration & dosage)</term><term>Domperidone (diagnostic use)</term><term>Domperidone (pharmacology)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (diagnostic use)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Antagonists (administration & dosage)</term><term>Dopamine Antagonists (diagnostic use)</term><term>Dopamine Antagonists (pharmacology)</term><term>Drug Administration Schedule</term><term>Guidelines as Topic</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (diagnostic use)</term><term>Levodopa (pharmacology)</term><term>Parkinson Disease (diagnosis)</term><term>Substantia Nigra (drug effects)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term><term>Domperidone</term><term>Dopamine Agonists</term><term>Dopamine Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Apomorphine</term><term>Domperidone</term><term>Dopamine Agonists</term><term>Dopamine Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term><term>Domperidone</term><term>Dopamine Agonists</term><term>Dopamine Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Decision Making</term><term>Drug Administration Schedule</term><term>Guidelines as Topic</term><term>Humans</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11295770</PMID><DateCreated><Year>2001</Year><Month>04</Month><Day>11</Day></DateCreated><DateCompleted><Year>2001</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>197-201</MedlinePgn></Pagination><Abstract><AbstractText>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders.</AbstractText><CopyrightInformation>Copyright 2001 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Istituto di Neurologia, Università Cattolica, Milano, Italy. alberto.albanese@rm.unicatt.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Brefel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chaudhuri</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Colosimo</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Eichhorn</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Melamed</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Van Laar</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zappia</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D003657">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004294">Domperidone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018492">Dopamine Antagonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017408">Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>31</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11295770</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Bonuccelli, U" sort="Bonuccelli, U" uniqKey="Bonuccelli U" first="U" last="Bonuccelli">U. Bonuccelli</name><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name><name sortKey="Chaudhuri, K R" sort="Chaudhuri, K R" uniqKey="Chaudhuri K" first="K R" last="Chaudhuri">K R Chaudhuri</name><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name><name sortKey="Eichhorn, T" sort="Eichhorn, T" uniqKey="Eichhorn T" first="T" last="Eichhorn">T. Eichhorn</name><name sortKey="Melamed, E" sort="Melamed, E" uniqKey="Melamed E" first="E" last="Melamed">E. Melamed</name><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name><name sortKey="Van Laar, T" sort="Van Laar, T" uniqKey="Van Laar T" first="T" last="Van Laar">T. Van Laar</name><name sortKey="Zappia, M" sort="Zappia, M" uniqKey="Zappia M" first="M" last="Zappia">M. Zappia</name></noCountry><country name="Italie"><noRegion><name sortKey="Albanese, A" sort="Albanese, A" uniqKey="Albanese A" first="A" last="Albanese">A. Albanese</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000460 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000460 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:11295770
|texte= Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:11295770" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |